Login to Your Account

Financings Roundup

Offering Adds $67.5M More for Optimer's Fidaxomicin

By Tom Wall

Monday, February 14, 2011
Optimer Pharmaceuticals Inc. continued to take care of its near-term cash needs in anticipation of a commercial launch of Clostridium difficile infection (CDI) drug fidaxomicin by raising gross proceeds of $67.5 million in an underwritten public offering of 6 million shares of common stock priced at $11.25 per share, about 10.5 percent below the previous day's closing price.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription